NASDAQ:AXSM - Axsome Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.15 +0.05 (+1.61 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$3.15
Today's Range$3.10 - $3.20
52-Week Range$2.05 - $6.45
Volume91,479 shs
Average Volume70,927 shs
Market Capitalization$79.63 million
P/E Ratio-2.54
Dividend YieldN/A
Beta-0.3
Axsome Therapeutics logoAxsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241

Debt

Debt-to-Equity Ratio0.47
Current Ratio2.95
Quick Ratio2.95

Price-To-Earnings

Trailing P/E Ratio-2.54
Forward P/E Ratio-2.92
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book4.77

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-28,940,000.00
Net MarginsN/A
Return on Equity-145.83%
Return on Assets-74.32%

Miscellaneous

Employees25
Outstanding Shares25,680,000
Market Cap$79.63

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics Inc (NASDAQ:AXSM) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.09. View Axsome Therapeutics' Earnings History.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Axsome Therapeutics.

What price target have analysts set for AXSM?

4 Wall Street analysts have issued 1-year price objectives for Axsome Therapeutics' shares. Their predictions range from $10.00 to $31.00. On average, they anticipate Axsome Therapeutics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Ratings for Axsome Therapeutics.

What is the consensus analysts' recommendation for Axsome Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a increase in short interest in June. As of June 29th, there was short interest totalling 1,804,508 shares, an increase of 103.1% from the June 15th total of 888,345 shares. Based on an average daily volume of 237,343 shares, the short-interest ratio is currently 7.6 days. Currently, 10.9% of the shares of the company are sold short. View Axsome Therapeutics' Current Options Chain.

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)
  • Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 43)
  • Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 35)
  • Dr. Robert Niecestro Ph.D., VP of Clinical & Regulatory (Age 67)
  • Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 43)

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Has Axsome Therapeutics been receiving favorable news coverage?

Media headlines about AXSM stock have trended positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axsome Therapeutics earned a daily sentiment score of 0.39 on Accern's scale. They also assigned media coverage about the company an impact score of 49.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Alethea Capital Management LLC (1.05%). View Institutional Ownership Trends for Axsome Therapeutics.

Which major investors are buying Axsome Therapeutics stock?

AXSM stock was acquired by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $3.15.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $79.63 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.


MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.